EP2956154A4 - Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels - Google Patents

Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels

Info

Publication number
EP2956154A4
EP2956154A4 EP14751148.9A EP14751148A EP2956154A4 EP 2956154 A4 EP2956154 A4 EP 2956154A4 EP 14751148 A EP14751148 A EP 14751148A EP 2956154 A4 EP2956154 A4 EP 2956154A4
Authority
EP
European Patent Office
Prior art keywords
mudulate
pcsk9
ldl
levels
low density
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14751148.9A
Other languages
German (de)
French (fr)
Other versions
EP2956154A2 (en
Inventor
Michael M Muehlemann
Thomas E Barta
Kyle D Monroe
Jonathan William Bourne
Margaret Thompson Reece
Vesa Nevalainen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRX Cardio LLC
Original Assignee
SRX Cardio LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRX Cardio LLC filed Critical SRX Cardio LLC
Publication of EP2956154A2 publication Critical patent/EP2956154A2/en
Publication of EP2956154A4 publication Critical patent/EP2956154A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP14751148.9A 2013-02-15 2014-02-15 Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels Withdrawn EP2956154A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361765423P 2013-02-15 2013-02-15
US201361836381P 2013-06-18 2013-06-18
PCT/US2014/016640 WO2014127316A2 (en) 2013-02-15 2014-02-15 Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels

Publications (2)

Publication Number Publication Date
EP2956154A2 EP2956154A2 (en) 2015-12-23
EP2956154A4 true EP2956154A4 (en) 2016-07-27

Family

ID=51354696

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14751148.9A Withdrawn EP2956154A4 (en) 2013-02-15 2014-02-15 Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels

Country Status (10)

Country Link
EP (1) EP2956154A4 (en)
JP (1) JP2016508722A (en)
KR (1) KR20150127622A (en)
CN (1) CN105378159A (en)
AU (1) AU2014216091A1 (en)
CA (1) CA2901436A1 (en)
HK (1) HK1219048A1 (en)
IL (1) IL240583A0 (en)
SG (1) SG11201506336XA (en)
WO (1) WO2014127316A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
WO2014145561A2 (en) 2013-03-15 2014-09-18 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
PT3143037T (en) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Alpha4beta7 integrin thioether peptide antagonists
EP3169403B1 (en) 2014-07-17 2024-02-14 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2016029037A1 (en) 2014-08-21 2016-02-25 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
JP2017535527A (en) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド Novel α4β7 peptide monomer and dimer antagonist
MA41022A (en) * 2014-11-24 2017-10-03 Shire Human Genetic Therapies LYSOSOMIAL TARGETING AND CORRESPONDING USES
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US10821106B2 (en) 2015-08-21 2020-11-03 Srx Cardio, Llc Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity
WO2017034990A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
US10568882B2 (en) 2015-08-21 2020-02-25 Srx Cardio, Llc Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
WO2017058113A1 (en) * 2015-09-28 2017-04-06 Agency For Science, Technology And Research Coating for metal nanoparticles
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CN109195618A (en) 2016-03-23 2019-01-11 领导医疗有限公司 Method for synthesizing 4 β of α, 7 peptide antagonists
MX2018016057A (en) 2016-06-24 2019-05-06 Hoffmann La Roche Compositions and methods for treating cardiovascular disease.
TW201823222A (en) * 2016-12-23 2018-07-01 財團法人生物技術開發中心 Compound, pharmaceutical composition and use thereof
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MA54261A (en) 2019-01-18 2022-04-27 Astrazeneca Ab PCSK9 INHIBITORS AND METHODS OF USE THEREOF
CA3146390A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11845808B2 (en) 2020-01-15 2023-12-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (en) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． Compositions of peptide inhibitors of interleukin-23 receptors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
UA104489C2 (en) * 2009-10-01 2014-02-10 Каділа Хелткере Лімітед Compounds for the treatment of dyslipidemia and related diseases
CN102206249B (en) * 2011-04-26 2013-07-03 中国农业科学院哈尔滨兽医研究所 Specific B cell epitope polypeptide of NS1 protein of encephalitis B virus and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NICOLA FERRI: "Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases", SCIENTIFICA, vol. 166, no. 7, 1 January 2012 (2012-01-01), pages 4334 - 21, XP055270158, DOI: 10.1016/S0140-6736(10)60284-X *
TIBOLLA G ET AL: "Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structurefunction relation to therapeutic inhibition", NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, MILAN, IT, vol. 21, no. 11, 23 June 2011 (2011-06-23), pages 835 - 843, XP028314065, ISSN: 0939-4753, [retrieved on 20110720], DOI: 10.1016/J.NUMECD.2011.06.002 *

Also Published As

Publication number Publication date
HK1219048A1 (en) 2017-03-24
KR20150127622A (en) 2015-11-17
AU2014216091A1 (en) 2015-09-03
IL240583A0 (en) 2015-09-24
SG11201506336XA (en) 2015-09-29
CN105378159A (en) 2016-03-02
JP2016508722A (en) 2016-03-24
CA2901436A1 (en) 2014-08-21
EP2956154A2 (en) 2015-12-23
WO2014127316A4 (en) 2014-12-04
WO2014127316A3 (en) 2014-10-09
WO2014127316A2 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
HK1219048A1 (en) Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels /kexin 9 (pcsk9) (ldl)
HK1243075A1 (en) Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
ZA201409210B (en) Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors
HK1257523A1 (en) Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
HK1207592A1 (en) Stable formulations containing anti-pcsk9 antibodies pcsk9
HK1216841A1 (en) Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) 9(pcsk9)
CO6910163A2 (en) Methods for reducing lipoprotein levels (a) by administering a protein convertase subtilisin kexin-9 inhibitor (pcsk9)
IL266066A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
EP2968266A4 (en) Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
HK1202804A1 (en) Treatment with anti-pcsk9 antibodies pcsk9
WO2012170607A3 (en) Use of pcsk9 antagonists
ZA201307499B (en) Compositions and methods comprising serine protease variants
MX2015016887A (en) Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9.
EP3182971A4 (en) Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
IL240437A0 (en) Serum fraction of platelet-rich fibrin
HK1213194A1 (en) Novel binding proteins for pcsk9 pcsk9
HK1257102A1 (en) Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use
FR2995225B1 (en) MICROFLUIDIC SYSTEM HAVING A BED OF MAGNETIC PARTICLES
SG11201510523QA (en) Pump housing made of a magnetic and a non-magnetic material
MX2017011879A (en) Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders.
PT2682123T (en) Biologically active food additive for normalizing the function of the thyroid gland
GB201306127D0 (en) Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9)
HK1218140A1 (en) Milk clotting aspartic protease enzyme composition
GB201602153D0 (en) Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9)
ZA201507890B (en) Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150915

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20160627

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/40 20060101ALI20160621BHEP

Ipc: A61K 45/06 20060101ALI20160621BHEP

Ipc: A61K 38/10 20060101AFI20160621BHEP

Ipc: C07K 7/06 20060101ALI20160621BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1219048

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20180409

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1219048

Country of ref document: HK